Access cutting-edge glioblastoma treatment through this clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.
Access glioblastoma specialists in Dallas at no cost
This study follows strict safety protocols and ethical guidelines
All study-related glioblastoma treatment provided free
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to characterize the safety and tolerability of these combinations in adult participants with glioblastoma (GBM). Arm B which was previously added to the protocol, has been permanently halted per the safety monitoring committees' decision on the safety findings of this arm.
Sponsor: Debiopharm International SA
Check if you qualify for this glioblastoma clinical trial in Dallas, TX
If you're searching for glioblastoma treatment options in Dallas, TX, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.